Green light for Ferring's testosterone treatment in Europe

Privately-held Swiss drugmaker Ferring Pharmaceuticals has announced the positive outcome of the European Decentralized Procedure (DCP) for Testavan (transdermal testosterone gel), its testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.

This process involves a country acting as a reference member state on behalf of all 31 European Economic Areas countries, with the Netherlands doing so in this case.

In Phase III trials, men treated with Testavan achieved normalized testosterone levels in three months, with improvements in quality of life and fatigue and early and sustained increase in erectile function score at both one and three months.